Clinical Trial Update: Study of Durvalumab+Olaparib or Durvalumab After Treatment With Durvalumab and Chemotherapy in Patients With Lung Cancer (ORION) [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating durvalumab with olaparib, or durvalumab after prior durvalumab plus chemotherapy, in non-small cell lung cancer; the study is active_no…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Durvalumab (durvalumab)
• Olaparib (Olaparib)

Snippet

Sponsor: AstraZeneca | Conditions: Non-small Cell Lung Cancer NSCLC | Phase 2 | Status: ACTIVE_NOT_RECRUITING | Results posted: 2022-12-12